

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/16, 9/70	A1	(11) International Publication Number: WO 99/55374 (43) International Publication Date: 4 November 1999 (04.11.99)
(21) International Application Number: PCT/US99/09374 (22) International Filing Date: 30 April 1999 (30.04.99) (30) Priority Data: 09/069,875 30 April 1998 (30.04.98) US (71) Applicant: CLOSURE MEDICAL CORPORATION [US/US]; 5250 Greens Dairy Road, Raleigh, NC 27616 (US). (72) Inventor: NARANG, Upvan; Apartment 205, 410 Shelly River Drive, Raleigh, NC 27609 (US). (74) Agents: OLIFF, James, A. et al.; Oliff & Berridge, PLC, P.O. Box 19928, Alexandria, VA 22320 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: USE OF AN ADHESIVE COMPOSITION OVER A BIOACTIVE POLYMERIZATION INITIATOR OR ACCELERATOR		
(57) Abstract A composition comprising a polymerizable adhesive monomer is applied over a biologically active initiator or accelerator for polymerization of the monomer. The biologically active initiator or accelerator is a medicament that provides a desired medical or therapeutic activity as well as enhancing polymerization of the adhesive.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF AN ADHESIVE COMPOSITION OVER A BIOACTIVE POLYMERIZATION INITIATOR OR ACCELERATOR

BACKGROUND OF THE INVENTION

1. Field of Invention

5 The invention relates to the use of monomer and polymer compositions as biomedical adhesives and sealants, and particularly to their use in conjunction with bioactive materials.

2. Description of Related Art

 Products in primary use for wound closure are surgical sutures and staples.
10 Sutures are recognized to provide adequate wound support. However, sutures cause additional trauma to the wound site (by reason of the need for the needle and suture to pass through tissue and the need to anesthetize the wound area via needle puncture) and are time-consuming to place, and, at skin level, can cause unattractive wound closure marks. Surgical staples have been developed to speed wound apposition and provide
15 improved cosmetic results. However, surgical staples also impose additional wound trauma and require the use of ancillary and often expensive devices for positioning and applying the staples. Both sutures and staples are especially problematic in pediatric cases where the patient may have a strong fear response and refuse to cooperate with their placement, and in geriatric cases where the skin tissue is weaker and prone to
20 tearing.

 As an alternate to surgical sutures and staples, adhesives have been used in wound closure. Similarly, adhesives have been proposed for use in wound covering and protection in such topical applications as surface lacerations, abrasions, burns, stomatitis, and other open surface wounds. One group of such adhesives is the 1,1-
25 disubstituted ethylene monomers, such as the monomeric forms of α -cyanoacrylates.

 For wound closure and covering using adhesives, mixtures of cyanoacrylate adhesives and medicaments have been developed. For example, U.S. Patent No. 5,684,042 to Greff et al. discloses a cyanoacrylate composition comprising an antimicrobially-effective amount of an iodine-containing antimicrobial agent. The
30 iodine-containing antimicrobial agent is dispersible in the cyanoacrylate composition

and does not cause premature polymerization of the cyanoacrylate adhesive (i.e., does not initiate polymerization).

U.S. Patent No. 3,483,870 to Coover, et al. discloses the use of methyl α -cyanoacrylate as a bone cement. The α -cyanoacrylate may be blended with antibiotics so long as the antibiotics do not cause early polymerization (i.e., do not act as polymerization initiators) or cause adverse effects on the healing process.

Another method for treating or preventing infections associated with wounding using adhesives involves layering a cyanoacrylate over a medicament on a wound site. For example, U.S. Patent No. 5,580,565 to Tighe, et al. discloses the use of a topical α -cyanoacrylate tissue adhesive to form a protective barrier over intact or broken skin to allow healing of the skin to occur. Polymerization of the α -cyanoacrylate adhesive is initiated by contact with skin moisture and tissue protein. Tighe et al. also disclose the use of α -cyanoacrylate adhesives as a protective layer over medicaments. The only medicament exemplified by Tighe et al. is cortisone, which does not initiate polymerization of cyanoacrylate monomer compositions.

Others have also disclosed the use of cyanoacrylate adhesives as coverings for medicaments. For example, Beasley et al. disclose application of antibiotics, such as vancomycin powder or tetracycline, to a wound, followed by covering of the wound with isobutyl cyanoacrylate. This type of treatment is disclosed as showing promise for treatment of bacterially infected tissues. (Beasley, J.D. et al., Effect of Antibiotics and Chemical Adhesives on Infected Wounds, Mil. Med. 136(6):566-569, 1971). However, neither of these antibiotics act to initiate polymerization of the cyanoacrylate.

The use of cyanoacrylate adhesives to cover bioactive agents is also disclosed in: Miles et al., Oral Surgery, Oral Medicine, Oral Pathology, Vol. 75, No. 3, 397-402 (using triamcinolone acetonide (Kenalog) or chlorhexidine digluconate (Peridex) as the bioactive agent); and Kaufman, R.S., The Laryngoscope, 1974, 793-804 (using dexamethasone sodium phosphate (Decadron) as the bioactive agent).

U.S. Patent No. 4,669,491 to Weisberg et al. discloses the use of biocides covered by protective acrylic artificial nails. The biocides may be acidic or phenolic, but are preferably selected so as not to affect the cure rate or the bond strength of the glue layer. They include thymol, chlorothymol, benzoic acid, p-hydroxybenzoate alkyl esters, 4- and 6-phenyl-2-chlorophenyl, carvocrol, hexachlorophene, nitroforans, allicin,

2-phenylphenol, boric acid, mercurials, and such antibiotics as Bacitracin and Griseofulvin, quaternary ammonium halides such as n-alkyldimethylbenzylammonium chloride, cetyl pyridinium bromide, 5-methyl-2-isopropyl-cyclohexanol, 2-bornanone, cineole, safrole, bornyl chloride, 2-phenoxyethanol, benzylalcohol and ethanol. The biocides are applied to human fingernails, then covered by solutions comprising cyanoacrylate adhesive. The biocides are applied to the natural fingernails in a solution, and the solution is allowed to dry, leaving the active biocides on the nails. The biocide-treated fingernails are roughened with an abrasive, then coated with a monomeric cyanoacrylate solution to form the artificial fingernails. The cyanoacrylate monomers are polymerized by the addition of a polymethacrylate ester composition containing a benzoyl peroxide catalyst. There is no suggestion of selecting the monomers and biocides such that the biocides affect polymerization.

U.S. Patents Nos. 4,764,377 and 4,892,736 to Goodson disclose the use of a therapeutic agent and a cyanoacrylate adhesive for treatment of periodontal diseases. The therapeutic agent is placed within the periodontal pocket, then covered by a mechanical maintenance system (which may be in the form of a layer of an adhesive film, such as n-butylcyanoacrylate), which holds the therapeutic agent in the periodontal pocket, allowing the therapeutic agent to be administered to the periodontal site. Goodson and co-workers also disclose this type of system in, for example, "J. Periodont. Res", 1990, Vol. 25, 243-249, and "Recent Advances in Periodontology", Vol. 11, 61-68. The therapeutic agents include antibacterial agents such as iodine, sulfonamides, mercurials, bisbiguanides, or phenolics; antibiotics such as tetracycline, neomycin, kanamycin, metranidazole, or canamycin; anti-inflammatory agents such as indomethacin, eugenol, or hydrocortisone; immunosuppressive or stimulatory agents such as methotrexate or levamasole; dentinal desensitizing agents such as strontium chloride or sodium fluoride; odor masking agents such as peppermint oil or chlorophyll; immune reagents such as immunoglobulin or antigens; local anesthetic agents such as lidocaine or benzocaine; nutritional agents such as amino acids, essential fats, and vitamin C; antioxidants such as alphatocopherol and butylated hydroxy toluene; lipopolysaccharide complexing agents such as polymyxin; or peroxides such as urea peroxide. There is no suggestion of selecting the monomers and biocides such that the biocides affect polymerization.

U.S. Patents Nos. 5,514,371 and 5,624,669 to Leung, et al. disclose the addition of a therapeutic agent in a cyanoacrylate composition. The cyanoacrylate adhesive forms a matrix for the therapeutic agent, with the therapeutic agent being released *in vivo* over time from the matrix during biodegradation of the polymer. The therapeutic agent is not used as a polymerization initiator or a polymerization rate modifier.

U.S. Patent No. 4,940,579 to Randen discloses a composition comprising a medicament and a cyanoacrylate adhesive. The composition is used to deliver medicaments to non-mucosal areas of mammal bodies. However, Randen does not disclose the use of medicaments as polymerization initiators and/or rate accelerators.

U.S. Patent No. 5,254,132 to Barley et al. discloses the use of cyanoacrylate adhesives in conjunction with antibiotics. The antibiotics are added to the cyanoacrylate compositions and stored in a sterile applicator for use in a single-dose application. The composition is maintained in a sealed container to avoid polymerization prior to application; therefore, the antibiotic does not initiate or accelerate polymerization of the adhesive composition.

Typically, when used in medical applications, cyanoacrylate adhesives are applied in monomeric form to the surfaces to be joined, sealed, or otherwise treated. Typically, *in situ* anionic polymerization of the monomer occurs, giving rise to the desired adhesive bond or covering. Initiation of polymerization *in situ* typically utilizes moisture and/or proteins naturally present in the tissue being treated. Thus, in applications where tissue fluids are present, it is not necessary to add polymerization initiators or rate accelerators to cyanoacrylate composition. However, sometimes it is desirable to apply the cyanoacrylate adhesives to dry tissues (i.e., tissues that are essentially free of tissue fluids or the like). In addition, to prolong the shelf life of these extremely reactive cyanoacrylate monomers, they are formulated with stabilizers to avoid their premature polymerization. In these situations, polymerization of the cyanoacrylate adhesive proceeds slowly, causing inconvenience to the user. To overcome this inconvenience, polymerization initiators and/or rate accelerators have been added to the cyanoacrylate adhesive composition.

When an initiator or accelerator is added to the composition, it is not added until immediately prior to application of the adhesive. For example, U.S. Patent No. 4,042,442 to Dombroski et al. discloses the addition of a polymerization initiator (either

caffeine or theobromine) to a cyanoacrylate adhesive composition. The caffeine or theobromine is added to the adhesive composition in one of two ways. In the first way, the caffeine or theobromine can be mixed with the cyanoacrylate adhesive composition by stirring just prior to application of the adhesive to the substrates to be joined. In the
5 second way, the caffeine or theobromine is dissolved in a volatile solvent, applied to the surfaces to be joined, the volatile solvent is allowed to evaporate, and then the cyanoacrylate adhesive composition is applied to the surfaces of the substrates to be joined.

Commonly assigned PCT Application No. WO 96/40797, the disclosure of
10 which is hereby incorporated in its entirety, discloses the incorporation of a polymerization initiator or polymerization rate modifier in an applicator tip. Incorporation of the initiator or the rate modifier into the applicator tip allows a level of control over the polymerization rate that cannot be achieved through reliance on polymerization initiators naturally present at the wound site. Incorporation of the
15 initiator and/or rate modifier into the applicator tip provides convenience to the user, since a single applicator is required, and no additional mixing is needed. However, this application does not disclose the use of a medicament as an initiator or accelerator of polymerization for monomeric cyanoacrylate compositions.

Although the use of medicaments in conjunction with cyanoacrylate adhesive
20 compositions is known, and the use of polymerization initiators with cyanoacrylate adhesive compositions is known, there exists a need to provide a method for delivering pharmaceutically-effective levels of medicaments to wound sites along with cyanoacrylate adhesives that is convenient, reliable, and effective. To address this need, the present invention provides methods and compositions that use pharmaceutically-
25 effective amounts of medicaments as polymerization initiators or accelerators for monomeric adhesive compositions.

SUMMARY OF THE INVENTION

According to the present invention, a medicament acts as both an initiator and/or
30 an accelerator of polymerization of a monomeric adhesive composition and as a pharmaceutically active material. As used herein, a polymerization initiator is any material that causes a cyanoacrylate composition applied to a substantially dry tissue

(i.e., in the substantial absence of plasma or like tissue fluids) to polymerize in less than 300 seconds at ambient temperature, for example approximately 21-25°C. Preferably, the initiator causes the cyanoacrylate composition to polymerize in less than 150 seconds, or more preferably less than 135 seconds at ambient temperature, for example, at approximately 21-25°C. As used herein, a polymerization accelerator is any material that accelerates the rate of polymerization of a cyanoacrylate composition such that polymerization that would normally take more than 300 seconds at ambient temperature, for example at approximately 21-25°C occurs in less than 300 seconds, preferably in less than 150 seconds, and more preferably in less than 135 seconds. The initiator or rate accelerator can be, for example, a catalyst, but can also be a material that is consumed or chemically modified during the polymerization reaction. The medicament can be any material that has both a pharmaceutical effect as applied and a polymerization initiating or rate accelerating activity, including, but not limited to, antibiotics, antimicrobials, antiseptics, bacteriocins, bacteriostats, disinfectants, steroids, anesthetics, fungicides, anti-inflammatory agents, antibacterial agents, antiviral agents, antitumor agents, and tissue growth promoting substances.

The invention provides, among other things, a method of closing, sealing, covering, and/or protecting deep and/or surface wounds, such as those resulting from surgery or from lacerations, burns, sores, abrasions, and the like. The method includes laying down a medicament onto a wound or sore and applying over the medicament a polymerizable monomer-containing composition whose polymerization is initiated or accelerated by the medicament.

In embodiments, the invention also provides a method of delivering a medicament locally or systemically to a human or animal by applying the medicament to a tissue site and applying over the medicament a polymerizable monomer-containing composition whose polymerization is initiated or accelerated by the medicament. As used herein, tissue includes any tissue of a human or animal, such as skin, mucous membranes, oral/nasal tissues, gastrointestinal tissues, organ tissues, tumors, non-keratinous tissue, etc.

The present invention also provides a kit comprising a saleable package containing (i) a container of a polymerizable monomer composition such as described herein, and (ii) a container of a medicament, preferably one that acts as a polymerization

initiator or polymerization rate modifier for said monomer composition. The containers can preferably be in the form of, or part of, an applicator or applicator system and are preferably sterilizable. For example, the package and its contents can preferably be sterilized simultaneously.

5

The present invention also provides a manufacture of a package comprising a polymerizable monomer composition and an instruction sheet for a method of delivering a medicament to a patient, the method comprising:

- 10 applying a pharmaceutically effective amount of a medicament to a tissue of said patient, and
- applying a polymerizable monomer composition onto the medicament, wherein the medicament is a polymerization initiator or polymerization rate accelerator and causes polymerization of the monomer composition to form a polymeric adhesive covering to said tissue.

15

The present invention provides several advantages over wound treating methods now in use, including the ability to:

- 20 a) control the molecular weight distribution of the polymerized or cross-linked material (through the use of the polymerization initiator and/or polymerization rate accelerator);
- b) control the setting time of the polymerized or cross-linked cyanoacrylate adhesive;
- c) control the flow properties of polymerizable cyanoacrylate compositions;
- d) provide a medicament to a patient while simultaneously providing
- 25 wound closure, protection, and/or coverage;
- e) provide a medicament to a patient through topical administration; and/or
- f) any combination of the above.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

30 According to the invention, a medicament is applied to a tissue prior to application of the monomer-containing composition. The medicament acts to initiate and/or accelerate polymerization of the monomer composition. Thus, the medicament provides not only a biological activity, but a chemical one as well.

Examples of such medicaments include, but are not limited to antibiotics, antimicrobials, antiseptics, bacteriocins, bacteriostats, disinfectants, steroids, anesthetics, fungicides, anti-inflammatory agents, antibacterial agents, antiviral agents, antitumor agents, growth promoters, and mixtures thereof.

5 Exemplary medicaments include, but are not limited to, quaternary ammonium halides such as benzalkonium chloride and benzethonium chloride; chlorhexidine sulfate; gentamicin sulfate; hydrogen peroxide; quinolone thioureas; silver salts, including, but not limited to, silver acetate, silver benzoate, silver carbonate, silver chloride, silver citrate, silver iodide, silver nitrate, and silver sulfate; sodium
10 hypochlorite; salts of sulfadiazine, including, but not limited to silver, sodium, and zinc salts; and mixtures thereof.

Preferable medicaments are those that are anions or help in radical generation or that are ion pairs or are themselves radicals.

15 In embodiments, the medicament is preferably a quaternary ammonium halide such as alkylbenzyltrimethylammonium chloride (benzalkonium chloride; BAC) with an alkyl containing 6-18 carbon atoms, its pure components, or mixtures thereof, or benzethonium chloride; or a salt of sulfadiazine, such as a silver, sodium, or zinc salt.

The medicaments can be tested for initiation ability by pipetting an appropriate volume of a solution of the medicament prepared in a volatile solvent in a differential
20 scanning calorimetric aluminum pan. The volatile solvent is allowed to dry under ambient conditions. Alternatively, the appropriate quantity of the medicament is dispensed directly onto the differential scanning calorimetric pan. In either of the abovementioned cases, 25 μ l of the chosen monomer solution is pipetted into the pan. The time taken for the monomer composition to polymerize to the point of a gel is the
25 polymerization time.

In embodiments, the composition can comprise other polymerization initiators and/or rate accelerators in addition to the medicament. Particular additional initiators for particular systems may be readily selected by one of skill in the art without undue experimentation. Suitable additional polymerization initiators for the cyanoacrylate
30 compositions include, but are not limited to, other medicaments; detergent compositions; surfactants: e.g., nonionic surfactants such as polysorbate 20 (e.g., Tween 20TM; ICI Americas), polysorbate 80 (e.g., Tween 80TM; ICI Americas), and poloxamers;

cationic surfactants such as tetrabutylammonium bromide and benzethonium chloride or its pure components; anionic surfactants such as, stannous octoate (tin (II) 2-ethylhexanoate), and sodium tetradecyl sulfate; and amphoteric or zwitterionic surfactants such as dodecyldimethyl(3-sulfopropyl) ammonium hydroxide, inner salt; amines, imines and amides, such as imidazole, tryptamine, urea, arginine and povidine; phosphines, phosphites and phosphonium salts, such as triphenylphosphine and triethyl phosphite; alcohols such as ethylene glycol; methyl gallate; ascorbic acid; tannins and tannic acid; inorganic bases and salts, such as sodium bisulfite, magnesium hydroxide, calcium sulfate and sodium silicate; sulfur compounds such as thiourea and polysulfides; polymeric cyclic ethers such as monensin, nonactin, crown ethers, calixarenes and polymeric epoxides; cyclic and acyclic carbonates, such as diethyl carbonate; phase transfer catalysts such as Aliquat™ 336 (General Mills, Minneapolis, MN); organometallics; manganese acetylacetonate; and radical initiators and radicals, such as di-t-butyl peroxide and azobisisobutyronitrile.

The polymerizable and/or cross-linkable material may also contain an initiator which is inactive until activated by a catalyst or accelerator (included within the scope of the term "initiator" as used herein). These initiators can be activated by appropriate stimulation such as heat and/or light (e.g., ultraviolet or visible light).

Compositions employed in the invention are preferably sterilizable.

The amount of medicament applied should be an amount sufficient to cause initiation or acceleration of the rate of polymerization upon contact and mixing of the medicament with the monomeric composition. The medicament should also be applied in a pharmaceutically-effective amount and should be selected in conjunction with the specific polymerizable monomeric compound such that the medicament will function as a polymerization initiator and/or rate accelerator for the chosen monomer. Such a selection process can easily be performed by one of skill in the art.

The medicament can have a pharmaceutical effect only at the site of application (i.e., limited to the tissue on/in which it is applied), or it can have a systemic effect (by systemic, it is not only meant that the medicament has an effect throughout the patient's body, but also at a specific site other than the site of application). In embodiments where the medicament is applied in an amount sufficient to show a systemic pharmaceutical activity, it can be absorbed, transported, or otherwise distributed to the

site or sites within the patient where the pharmaceutical activity is desired, e.g., through the cardiovascular or lymph systems.

Depending on the particular requirements of the user, the medicament and adhesive compositions of this invention can be applied by any appropriate device, which can be the same or different for the medicament and adhesive composition. Examples include, but are not limited to, a glass stirring rod, sterile brush, or medicine dropper. In many situations a pump or pressurized aerosol dispensing package is preferred in which the adhesive composition is in solution with a compatible anhydrous propellant. A preferred device is an absorbent swab or wipe.

The medicament may be in the form of a solid, such as a powder or a solid film, or in the form of a liquid, such as a watery, viscous, or paste-like material. The medicament may also be compounded with a variety of additives, such as surfactants or emulsifiers, and vehicles.

The methods of this invention can be used to join together two surfaces, as a replacement for or in addition to sutures, by applying the present compositions to opposing wound surfaces that are then held together while polymerization proceeds. The methods of this invention can also be used to coat, protect, or otherwise cover surface, superficial, or otherwise topical wounds or pathologies including, but not limited to, superficial lacerations, abrasions, burns, sores, and stomatitis. The methods of the invention can also be used on tissues that do not show any signs of tissue damage. For example, the methods can be used to deliver medicaments to a patient through healthy tissue. They can also be used, for example, to locally deliver medicaments to tissues such as tumors or organs.

In one embodiment, the present invention provides a replacement for sutures and includes a method of delivering a medicament to a tissue by forming a biocompatible film across abutted tissue surfaces, comprising: (a) holding together at least two tissue surfaces to form abutted tissue surfaces, (b) applying a medicament which is a polymerization initiator or polymerization rate accelerator to the abutted tissue surfaces, (c) applying on to the medicament and across the abutted tissue surfaces a polymerizable adhesive monomer composition, and (d) allowing the composition to polymerize and form a biocompatible film on the abutted tissue surfaces. A subsequent coating may be applied immediately after application of a previous coating or after a

previous coating has been completely polymerized. Preferably, the monomer composition applied to the abutted tissue surface is allowed to at least partially polymerize prior to subsequent coatings or applications of additional monomer composition. A coating of an adhesive composition having a monomer different from
5 the monomer of the first or previous coating may be applied as the second or subsequent coating.

Addition of a plasticizing agent and acidic stabilizing agent can cause such a polymer coating to have sufficient bond strength and flexibility even with significant film or coating thicknesses. Suitable film thickness range from 0.1 mm to 2.0 mm or
10 3.0 mm or higher, preferably from 0.2 mm to 1.5 mm, and more preferably from 0.4 mm to 0.8 mm.

In embodiments, the biocompatible film formed as a replacement for sutures may have an *in vivo* film strength of at least 70 mm Hg of vacuum pressure required to induce wound failure, generally from 70 mm Hg to 400 mm Hg of vacuum pressure
15 required to induce wound failure, preferably from 90 mm Hg to 400 mm Hg of vacuum pressure required to induce wound failure, and more preferably from 100 mm Hg to 400 mm Hg of pressure required to induce wound failure.

When repairing injured tissues (for example, to control bleeding), the invention comprises first sponging the site to be repaired to remove superficial or body tissue
20 fluids. Desired bonding of tissues or hemostasis can also proceed well in the presence of blood and other body fluids as well as on dry tissue. The bonds formed are of adequate flexibility and strength to withstand normal movement of tissue. In addition, bond strength is maintained as natural wound healing proceeds.

In another embodiment, the present invention is directed to a method of treating
25 a superficial or topical pathology, including, but not limited to a skin wound such as a superficial laceration, burn, or abrasion, or a sore on a mucous membrane. The method comprises (a) applying a medicament that is a polymerization initiator or rate accelerator to the affected tissue, (b) applying a polymerizable monomer-containing composition over the medicament; (c) allowing the composition to polymerize; and (d) optionally,
30 applying the composition at least once more to the same site.

Suitable film thickness for such topical applications is preferably between 1 and 10,000 μm , for example between 1 and 1000 μm . In embodiments, the biocompatible

film so formed may have a film strength of at least 5 mm Hg, such as 5-400 mm Hg, preferably from 50-400 mm Hg.

In embodiments, the present invention provides a method of delivering a medicament to a tissue by (a) applying a medicament that is a polymerization initiator and/or polymerization rate accelerator to a site (e.g., directly to tissue); (b) applying a polymerizable monomer-containing composition over the medicament; and (c) optionally, applying the composition at least once more to the same site. Suitable film thickness and strength are preferably those disclosed above for other uses.

In embodiments, the medicament is released to the tissue to which it is in contact at a constant, or near constant, rate over a period of time while in contact with the affected tissue.

The present invention also provides a kit for delivering a medicament to a patient. The kit comprises a container with a polymerizable monomer composition, such as a cyanoacrylate adhesive. The kit also comprises another container with a medicament. The medicament is selected so that it functions in conjunction with the packaged polymerizable monomer composition to initiate polymerization of the monomer or modify (e.g., accelerate) the rate of polymerization for the monomer to form a polymeric adhesive. The proper combination of medicament and polymerizable monomer can be determined easily by one of skill in the art. The medicament is supplied in the kit in an amount that will be pharmaceutically effective when applied topically (i.e., directly to tissue).

The monomer composition, in embodiments, is preferably a monomeric (including prepolymeric) adhesive composition. In embodiments, the monomer is a 1,1-disubstituted ethylene monomer, e.g., an α -cyanoacrylate. Preferred monomer compositions of the present invention and polymers formed therefrom are useful as tissue adhesives, sealants for preventing bleeding or for covering open wounds, and in other biomedical applications. They find uses in, for example, apposing surgically incised or traumatically lacerated tissues; retarding blood flow from wounds; drug delivery; dressing burns; dressing skin or other superficial or surface wounds (such as abrasions, chaffed or raw skin, and/or stomatitis); and aiding repair and regrowth of living tissue.

Monomers that may be used in this invention are readily polymerizable, e.g. anionically polymerizable or free radical polymerizable, or polymerizable by zwitterions or ion pairs to form polymers. Such monomers include those that form polymers, that may, but do not need to, biodegrade. Such monomers are disclosed in, for example,
 5 U.S. Patent No. 5,328,687 to Leung, et al., which is hereby incorporated in its entirety by reference herein.


Useful 1,1-disubstituted ethylene monomers include, but are not limited to, monomers of the formula:




10 wherein X and Y are each strong electron withdrawing groups, and R is H, $-\text{CH}=\text{CH}_2$, or, provided that X and Y are both cyano groups, a C_1 - C_4 alkyl group.

Examples of monomers within the scope of formula (I) include alpha-cyanoacrylates, vinylidene cyanides, C_1 - C_4 alkyl homologues of vinylidene cyanides, dialkyl methylene malonates, acylacrylonitriles, vinyl sulfinates and vinyl sulfonates of
 15 the formula $\text{CH}_2=\text{CX}'\text{Y}'$ wherein X' is $-\text{SO}_2\text{R}'$ or $-\text{SO}_3\text{R}'$ and Y' is $-\text{CN}$, $-\text{COOR}'$, $-\text{COCH}_3$, $-\text{SO}_2\text{R}'$ or $-\text{SO}_3\text{R}'$, and R' is H or hydrocarbyl.


Preferred monomers of formula (I) for use in this invention are alpha-cyanoacrylates. These monomers are known in the art and have the formula



20 wherein R^2 is hydrogen and R^3 is a hydrocarbyl or substituted hydrocarbyl group; a group having the formula $-\text{R}^4-\text{O}-\text{R}^5-\text{O}-\text{R}^6$, wherein R^4 is a 1,2-alkylene group having 2-4 carbon atoms, R^5 is an alkylene group having 2-4 carbon atoms, and R^6 is an alkyl group having 1-6 carbon atoms; or a group having the formula



wherein R⁷ is



wherein n is 1-10, preferably 1-5 carbon atoms and R⁸ is an organic moiety.

Examples of suitable hydrocarbyl and substituted hydrocarbyl groups include
 5 straight chain or branched chain alkyl groups having 1-16 carbon atoms; straight chain
 or branched chain C₁-C₁₆ alkyl groups substituted with an acyloxy group, a haloalkyl
 group, an alkoxy group, a halogen atom, a cyano group, or a haloalkyl group; straight
 chain or branched chain alkenyl groups having 2 to 16 carbon atoms; straight chain or
 branched chain alkynyl groups having 2 to 12 carbon atoms; cycloalkyl groups; aralkyl
 10 groups; alkylaryl groups; and aryl groups.

The organic moiety R⁸ may be substituted or unsubstituted and may be straight
 chain, branched or cyclic, saturated, unsaturated or aromatic. Examples of such organic
 moieties include C₁-C₈ alkyl moieties, C₂-C₈ alkenyl moieties, C₂-C₈ alkynyl moieties,
 C₃-C₁₂ cycloaliphatic moieties, aryl moieties such as phenyl and substituted phenyl and
 15 aralkyl moieties such as benzyl, methylbenzyl and phenylethyl. Other organic moieties
 include substituted hydrocarbon moieties, such as halo (e.g., chloro-, fluoro- and bromo-
 substituted hydrocarbons) and oxy- (e.g., alkoxy substituted hydrocarbons) substituted
 hydrocarbon moieties. Preferred organic radicals are alkyl, alkenyl and alkynyl moieties
 having from 1 to about 8 carbon atoms, and halo-substituted derivatives thereof.
 20 Particularly preferred are alkyl moieties of 4 to 6 carbon atoms.

In the cyanoacrylate monomer of formula (II), R³ is preferably an alkyl group
 having 1-10 carbon atoms or a group having the formula -AOR⁹, wherein A is a divalent
 straight or branched chain alkylene or oxyalkylene moiety having 2-8 carbon atoms, and
 R⁹ is a straight or branched alkyl moiety having 1-8 carbon atoms.


25 Examples of groups represented by the formula -AOR⁹ include 1-methoxy-2-
 propyl, 2-butoxy ethyl, isopropoxy ethyl, 2-methoxy ethyl, and 2-ethoxy ethyl.

Preferred α-cyanoacrylate monomers used in this invention include 2-octyl
 cyanoacrylate, dodecyl cyanoacrylate, 2-ethylhexyl cyanoacrylate, butyl cyanoacrylate,
 methyl cyanoacrylate, 3-methoxybutyl cyanoacrylate, 2-butoxyethyl cyanoacrylate, 2-
 30 isopropoxyethyl cyanoacrylate, or 1-methoxy-2-propyl cyanoacrylate.

The α -cyanoacrylates of formula (II) can be prepared according to methods known in the art. U.S. Patents Nos. 2,721,858 and 3,254,111, each of which is hereby incorporated in their entirety by reference herein, disclose methods for preparing α -cyanoacrylates. For example, the α -cyanoacrylates can be prepared by reacting an alkyl cyanoacetate with formaldehyde in a non-aqueous organic solvent and in the presence of a basic catalyst, followed by pyrolysis of the anhydrous intermediate polymer in the presence of a polymerization inhibitor. The α -cyanoacrylate monomers prepared with low moisture content and essentially free of impurities are preferred for biomedical use.

The α -cyanoacrylates of formula (II) wherein R^3 is a group having the formula $R^4-O-R^5-O-R^6$ can be prepared according to the method disclosed in U.S. Patent No. 4,364,876 to Kimura et al., which is hereby incorporated in its entirety by reference. In the Kimura et al. method, the α -cyanoacrylates are prepared by producing a cyanoacetate by esterifying cyanoacetic acid with an alcohol or by transesterifying an alkyl cyanoacetate and an alcohol; condensing the cyanoacetate and formaldehyde or para-formaldehyde in the presence of a catalyst at a molar ratio of 0.5-1.5:1, preferably 0.8-1.2:1, to obtain a condensate; depolymerizing the condensation reaction mixture either directly or after removal of the condensation catalyst to yield crude cyanoacrylate; and distilling the crude cyanoacrylate to form a high purity cyanoacrylate.


The α -cyanoacrylates of formula (II) wherein R^3 is a group having the formula



can be prepared according to the procedure described in U.S. Patent No. 3,995,641 to Kronenthal et al., which is hereby incorporated in its entirety by reference. In the Kronenthal et al. method, such α -cyanoacrylate monomers are prepared by reacting an alkyl ester of an α -cyanoacrylic acid with a cyclic 1,3-diene to form a Diels-Alder adduct which is then subjected to alkaline hydrolysis followed by acidification to form the corresponding α -cyanoacrylic acid adduct. The α -cyanoacrylic acid adduct is preferably esterified by an alkyl bromoacetate to yield the corresponding carbalkoxymethyl α -cyanoacrylate adduct. Alternatively, the α -cyanoacrylic acid adduct may be converted to the α -cyanoacrylyl halide adduct by reaction with thionyl

chloride. The α -cyanoacrylyl halide adduct is then reacted with an alkyl hydroxyacetate or a methyl substituted alkyl hydroxyacetate to yield the corresponding carbalkoxymethyl α -cyanoacrylate adduct or carbalkoxy alkyl α -cyanoacrylate adduct, respectively. The cyclic 1,3-diene blocking group is finally removed and the carbalkoxy methyl α -cyanoacrylate adduct or the carbalkoxy alkyl α -cyanoacrylate adduct is converted into the corresponding carbalkoxy alkyl α -cyanoacrylate by heating the adduct in the presence of a slight deficit of maleic anhydride.

Examples of monomers of formula (II) include cyanopentadienoates and α -cyanoacrylates of the formula:



wherein Z is $-\text{CH}=\text{CH}_2$, and R^3 is as defined above. The monomers of formula (III) wherein R^3 is an alkyl group of 1-10 carbon atoms, i.e., the 2-cyanopenta-2,4-dienoic acid esters, can be prepared by reacting an appropriate 2-cyanoacetate with acrolein in the presence of a catalyst such as zinc chloride. This method of preparing 2-cyanopenta-2,4-dienoic acid esters is disclosed, for example, in U.S. Patent No. 3,554,990, which is hereby incorporated in its entirety by reference.

Preferred monomers are alkyl α -cyanoacrylates and more preferably octyl α -cyanoacrylates, especially 2-octyl α -cyanoacrylate. Monomers utilized in the present application should be very pure and contain few impurities (e.g., surgical grade).

The composition may optionally also include at least one plasticizing agent that imparts flexibility to the polymerized monomer formed on the wound, incision, or abrasion. The plasticizing agent preferably contains little or no moisture and should not significantly affect the polymerization of the monomer.

Examples of suitable plasticizers include acetyl tributyl citrate, dimethyl sebacate, triethyl phosphate, tri(2-ethylhexyl)phosphate, tri(p-cresyl) phosphate, glyceryl triacetate, glyceryl tributyrates, diethyl sebacate, dioctyl adipate, isopropyl

myristate, butyl stearate, lauric acid, trioctyl trimellitate, dioctyl glutarate and mixtures thereof. Preferred plasticizers are tributyl citrate and acetyl tributyl citrate. In embodiments, suitable plasticizers include polymeric plasticizers, such as polyethylene glycol (PEG) esters and capped PEG esters or ethers, polyester glutarates and polyester adipates.

The composition may also optionally include at least one stabilizing agent that inhibits polymerization. Such stabilizing agents may also include mixtures of anionic stabilizing agents and radical stabilizing agents.

Examples of suitable anionic stabilizing agents include, but are not limited to, sultones (e.g., α -chloro- α -hydroxy-*o*-toluenesulfonic acid- γ -sultone), sulfur dioxide, sulfuric acid, sulfonic acid, lactone, boron trifluoride, organic acids, such as acetic acid or phosphoric acid, alkyl sulfate, alkyl sulfite, 3-sulfolene, alkylsulfone, alkyl sulfoxide, mercaptan, and alkyl sulfide and mixtures thereof. Preferable anionic stabilizing agents are acidic stabilizing agents of organic acids such as acetic acid or phosphoric acid. In embodiments, the amount of sulfur dioxide stabilizer is less than 100 ppm, preferably 5-75 ppm, and more preferably from about 20-50 ppm. The amount of sultone and/or trifluoroacetic acid is about 500-3000 ppm.

Examples of suitable radical stabilizing agents include hydroquinone, hydroquinone monomethyl ether, catechol, pyrogallol, benzoquinone, 2-hydroxybenzoquinone, *p*-methoxy phenol, *t*-butyl catechol, butylated hydroxy anisole (BHA), butylated hydroxy toluene, and *t*-butyl hydroquinone. In embodiments, the amount of BHA is about 1,000-5,000 ppm.

Suitable acidic stabilizing agents include those having aqueous pK_a ionization constants ranging from -12 to 7, about -5 to about 7, preferably from about -3.5 to about 6. For example, suitable acidic stabilizing agents include: hydrogen sulfide (pK_a 7.0), carbonic acid (pK_a 6.4), triacetylmethane (pK_a 5.9), acetic acid (pK_a 4.8), benzoic acid (pK_a 4.2), 2,4-dinitrophenol (pK_a 4.0), formic acid (pK_a 3.7), nitrous acid (pK_a 3.3), hydrofluoric acid (pK_a 3.2), chloroacetic acid (pK_a 2.9), phosphoric acid (pK_a 2.2), dichloroacetic acid (pK_a 1.3), trichloroacetic acid (pK_a 0.7), 2,4,6-trinitrophenol (picric acid) (pK_a 0.3), trifluoroacetic acid (pK_a 0.2), sulfuric acid (pK_a -3.0), sulfurous acid, and mixtures thereof. In embodiments, the amount of trifluoroacetic acid is about 500-1,500 ppm. Combinations of the above stabilizers, such as sulfur dioxide and

sulfuric acid, boron trifluoride and sulfuric acid, sulfur dioxide and chloroacetic acid, boron trifluoride and chloroacetic acid, sulfur dioxide and trifluoroacetic acid, and boron trifluoride and trifluoroacetic acid can be used.

When adding the acidic stabilizing agents mentioned above to the adhesive composition, the addition of plasticizing agents in amounts ranging from about 0.5 wt.% to about 16 wt.%, preferably from about 3 wt.% to about 9 wt.%, and more preferably from about 5 wt.% to about 7 wt.% provides increased film strength (e.g., toughness) of the polymerized monomer over polymerized monomers having amounts of plasticizing agents and acidic stabilizing agents outside of the above ranges.

The concentration of the acidic stabilizing agents utilized may vary depending on the strength of the acid. For example, when using acetic acid, a concentration of 80-200 ppm (wt/wt), preferably 90-180 ppm (wt/wt), and more preferably 100-150 ppm (wt/wt) may be utilized. When using a stronger acid such as phosphoric acid, a concentration range of 20-80 ppm (wt/wt), preferably, 30-70 ppm (wt/wt) and more preferably 40-60 ppm (wt/wt) may be utilized. In embodiments, the amount of trifluoroacetic acid is about 100 to 3000 ppm, preferably 500-1500 ppm. In other embodiments, the amount of phosphoric acid is about 10-200 ppm, preferably about 50-150 ppm, and more preferably about 75-125 ppm.

The compositions of the present invention may also include at least one biocompatible agent effective to reduce active formaldehyde concentration levels produced during *in vivo* biodegradation of the polymer (also referred to herein as "formaldehyde concentration reducing agents"). Preferably, this component is a formaldehyde scavenger compound. Examples of formaldehyde scavenger compounds useful in this invention include sulfites; bisulfites; mixtures of sulfites and bisulfites; ammonium sulfite salts; amines; amides; imides; nitriles; carbamates; alcohols; mercaptans; proteins; mixtures of amines, amides, and proteins; active methylene compounds such as cyclic ketones and compounds having a β -dicarbonyl group; and heterocyclic ring compounds free of a carbonyl group and containing an NH group, with the ring made up of nitrogen or carbon atoms, the ring being unsaturated or, when fused to a phenyl group, being unsaturated or saturated, and the NH group being bonded to a carbon or a nitrogen atom, which atom is directly bonded by a double bond to another carbon or nitrogen atom.

Bisulfites and sulfites useful as the formaldehyde scavenger compound in this invention include alkali metal salts such as lithium, sodium and potassium salts, and ammonium salts, for example, sodium bisulfite, potassium bisulfite, lithium bisulfite, ammonium bisulfite, sodium sulfite, potassium sulfite, lithium sulfite, ammonium sulfite, and the like.

Examples of amines useful in this invention include the aliphatic and aromatic amines such as, for example, aniline, benzidine, aminopyrimidine, toluene-diamine, triethylenediamine, diphenylamine, diaminodiphenylamine, hydrazines and hydrazide.

Suitable proteins include collagen, gelatin, casein, soybean protein, vegetable protein, keratin, and glue. The preferred protein for use in this invention is casein.

Suitable amides for use in this invention include urea, cyanamide, acrylamide, benzamide, and acetamide. Urea is a preferred amide.

Suitable alcohols include phenols, 1,4-butanediol, d-sorbitol, and polyvinyl alcohol.

Examples of suitable compounds having a b-dicarbonyl group include malonic acid, acetylacetone, ethylacetone, acetate, malonamide, diethylmalonate or another malonic ester.

Preferred cyclic ketones for use in this invention include cyclohexanone or cyclopentanone.

Examples of suitable heterocyclic compounds for use as the formaldehyde scavenger in this invention are disclosed, for example, in U.S. Patent No. 4,127,382 (Perry) which is hereby incorporated in its entirety by reference. Such heterocyclic compounds include, for example, benzimidazole, 5-methyl benzimidazole, 2-methylbenzimidazole, indole, pyrrole, 1,2,4-triazole, indoline, benzotriazole, indoline, and the like.

A preferred formaldehyde scavenger for use in this invention is sodium bisulfite.

In practicing the present invention, the formaldehyde concentration reducing agent, e.g., formaldehyde scavenger compound, is added in an effective amount to the cyanoacrylate. The "effective amount" is that amount sufficient to reduce the amount of formaldehyde generated during subsequent *in vivo* biodegradation of the polymerized cyanoacrylate. This amount will depend on the type of active formaldehyde

concentration reducing agent, and can be readily determined without undue experimentation by those skilled in the art.

The formaldehyde concentration reducing agent may be used in this invention in either free form or in microencapsulated form. Other compositions are exemplified by
5 U.S. Patent Application Serial No. 08/714,288, incorporated by reference herein in its entirety.

When microencapsulated, the formaldehyde concentration reducing agent is released from the microcapsule continuously over a period of time during the *in vivo* biodegradation of the cyanoacrylate polymer.

10 For purposes of this invention, the microencapsulated form of the formaldehyde concentration reducing agent is preferred because this embodiment prevents or substantially reduces polymerization of the cyanoacrylate monomer by the formaldehyde concentration reducing agent, which increases shelf-life and facilitates handling of the monomer composition during use.

15 Microencapsulation of the formaldehyde scavenger can be achieved by many known microencapsulation techniques. For example, microencapsulation can be carried out by dissolving a coating polymer in a volatile solvent, e.g., methylene chloride, to a polymer concentration of about 6% by weight; adding a formaldehyde scavenger compound in particulate form to the coating polymer/solvent solution under agitation to
20 yield a scavenger concentration of 18% by weight; slowly adding a surfactant-containing mineral oil solution to the polymer solution under rapid agitation; allowing the volatile solvent to evaporate under agitation; removing the agitator; separating the solids from the mineral oil; and washing and drying the microparticles. The size of the microparticles will range from about 0.001 to about 1000 microns.

25 The coating polymer for microencapsulating the formaldehyde concentration reducing agent should be polymers which undergo *in vivo* bioerosion, preferably at rates similar to or greater than the cyanoacrylate polymer formed by the monomer, and should have low inherent moisture content. Such bioerosion can occur as a result of the physical or chemical breakdown of the encapsulating material, for example, by the
30 encapsulating material passing from solid to solute in the presence of body fluids, or by biodegradation of the encapsulating material by agents present in the body.

Examples of coating materials which can be used to microencapsulate the formaldehyde concentration reducing agent include polyesters, such as polyglycolic acid, polylactic acid, poly-1,4-dioxo-2-one, polyoxaltes, polycarbonates, copolymers of polyglycolic acid and polylactic acid, polycaprolactone, poly-b-hydroxybutyrate, copolymers of epsilon-caprolactone and delta-valerolactone, copolymers of epsilon-caprolactone and DL-dilactide, and polyester hydrogels; polyvinylpyrrolidone; polyamides; gelatin; albumin; proteins; collagen; poly(orthoesters); poly(anhydrides); poly(alkyl-2-cyanoacrylates); poly(dihydropyrans); poly(acetals); poly(phosphazenes); poly(urethanes); poly(dioxinones); cellulose; and starches.

Examples of surfactants which can be added to the mineral oil include those commercially available under the designations Triton X-100™ (Rohm and Haas), Tween 20™ (ICI Americas), and Tween 80™ (ICI Americas).

The composition may also optionally include at least one thickening agent. Suitable thickeners include, for example, polycyanoacrylates, polylactic acid, poly-1,4-dioxo-2-one, polyoxalates, polyglycolic acid, lactic-glycolic acid copolymers, polycaprolactone, lactic acid-caprolactone copolymers, poly-3-hydroxybutyric acid, polyorthoesters, polyalkyl acrylates, copolymers of alkylacrylate and vinyl acetate, polyalkyl methacrylates, and copolymers of alkyl methacrylates and butadiene. Examples of alkyl methacrylates and acrylates are poly(2-ethylhexyl methacrylate) and poly(2-ethylhexyl acrylate), also poly(butylmethacrylate) and poly(butylacrylate), also copolymers of various acrylate and methacrylate monomers, such as poly(butylmethacrylate-co-methylacrylate).

To improve the cohesive strength of adhesives formed from the compositions of this invention, difunctional monomeric cross-linking agents may be added to the monomer compositions of this invention. Such crosslinking agents are known. U.S. Patent No. 3,940,362 to Overhults, which is hereby incorporated in its entirety by reference, discloses such cross-linking agents. Examples of suitable crosslinking agents include alkyl bis(2-cyanoacrylates), triallyl isocyanurates, alkylene diacrylates, alkylene dimethacrylates, trimethylol propane triacrylate, and alkyl bis(2-cyanoacrylates). A catalytic amount of an amine activated free radical initiator or rate modifier may be added to initiate polymerization or to modify the rate of polymerization of the cyanoacrylate monomer/crosslinking agent blend.

The compositions of this invention may further contain fibrous reinforcement and colorants, i.e., dyes and pigments. Examples of suitable fibrous reinforcement include PGA microfibrils, collagen microfibrils, cellulosic microfibrils, and olefinic microfibrils. Examples of suitable colorants include 1-hydroxy-4-[4-methylphenyl-amino]-9,10 anthracenedione (D+C violet No. 2); disodium salt of 6-hydroxy-5-[(4-sulphophenyl)axo]-2-naphthalene-sulfonic acid (FD+C Yellow No. 6); 9-(o-carboxyphenyl)-6-hydroxy-2,4,5,7-tetraiodo-3H-xanthen-3-one, disodium salt, monohydrate (FD+C Red No. 3); 2-(1,3-dihydro-3-oxo-5-sulfo-2H-indol-2-ylidene)-2,3-dihydro-3-oxo-1H-indole-5-sulfonic acid disodium salt (FD+C Blue No. 2); and [phtha-locyaninato (2-)] copper.

Other compositions that are contemplated by the present invention are exemplified by U.S. Patents Nos. 5,624,669; 5,582,834; 5,575,997; 5,514,371; 5,514,372; and 5,259,835; the disclosures of all of which are hereby incorporated in their entirety by reference.

Example

A sample of 120 microliters of 1000 ppm BAC solution in methanol was tested for its initiation property with 2-octyl cyanoacrylate in accordance with the method described above. The following polymerization times were obtained:

	<u>Sample Number</u>	<u>Set Time (seconds)</u>
20	1	109
	2	106
	3	111
	4	121
	5	102
25	6	101
	7	109
	8	57
	9	126

WHAT IS CLAIMED IS:

1. A kit for delivering a medicament to a patient, comprising a package containing:

5 a first container that contains a polymerizable monomer composition, and

a second container that contains a medicament.

2. The kit of claim 1, wherein said medicament is a polymerization initiator or polymerization rate accelerator and causes polymerization of the monomer composition to form a polymeric adhesive.

10 3. The kit of claim 1 or 2, wherein the medicament is present in a pharmaceutically effective amount for topical application on tissue.

4. The kit of claim 2, wherein the superficial tissue is skin.

5. The kit of any one of claims 1-3, wherein the medicament is selected from the group consisting of antibiotics, antimicrobials, antiseptics, bacteriocins, bacteriostats, disinfectants, steroids, fungicides, anti-inflammatory agents, antibacterial agents, antiviral agents, antitumor agents, growth promoters, and mixtures thereof.

6. The kit of claim 1 or 2, wherein the polymerizable monomer is a 1,1-disubstituted ethylene monomer.

20 7. The kit of claim 1, 2 or 6, wherein the polymerizable monomer is a cyanoacrylate.

8. The kit of any one of claims 1-3 or 5, wherein the medicament is selected from the group consisting of quaternary ammonium halides, salts of sulfadiazine, and salts of silver.

25 9. The kit of any one of claims 1-3, 5 or 8, wherein the medicament is a quaternary ammonium halide selected from the group consisting of alkylbenzyltrimethylammonium chloride with an alkyl containing 6-18 carbon atoms, its pure components, or mixtures thereof; and benzethonium chloride.

30 10. The kit of any one of claims 1-3, 5 or 8-9, wherein the medicament is a salt of sulfadiazine selected from the group consisting of a silver salt, a sodium salt, and a zinc salt.

11. The kit of claim 7, wherein the kit is sterilized.

12. The kit of claim 2, wherein the patient is an animal.

13. Manufacture of a package comprising a polymerizable monomer composition and an instruction sheet for a method of delivering a medicament to a patient, the method comprising:

5 applying a pharmaceutically effective amount of a medicament to a tissue of said patient, and
 applying a polymerizable monomer composition onto the medicament, wherein the medicament is a polymerization initiator or polymerization rate accelerator and causes polymerization of the monomer composition to form a polymeric adhesive covering on said tissue.

10 14. Manufacture according to claim 13, wherein the medicament has a local pharmaceutical effect on the tissue to which it is applied.

 15. Manufacture according to claim 13 or 14, wherein the medicament has a systemic pharmaceutical effect on said patient.

15 16. Manufacture according to any one of claims 13-15, wherein the polymerizable monomer is a 1,1-disubstituted ethylene monomer.

 17. Manufacture according to any one of claims 13-15, wherein the polymerizable monomer is a cyanoacrylate.

 18. Manufacture according to any one of claims 13-17, wherein the medicament is an anion, participates in radical generation, is an ion pair, or is a radical.

 19. Manufacture according to any one of claims 13-18, wherein the medicament is applied by spraying, brushing, swabbing, dripping, wiping, or dusting.

20 20. Manufacture according to any one of claims 13-19, wherein the medicament is selected from the group consisting of antibiotics, antimicrobials, antiseptics, bacteriocins, bacteriostats, disinfectants, steroids, fungicides, anti-inflammatory agents, antibacterial agents, antiviral agents, antitumor agents, growth promoters, and mixtures thereof.

PC1/US 99/09374

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K47/16 A61K9/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 684 042 A (BYRAM MICHAEL M ET AL) 4 November 1997 (1997-11-04) column 6, line 45 -column 7, line 57 column 10; table 1 ---	1-20
X	US 4 797 282 A (WAHLIG HELMUT ET AL) 10 January 1989 (1989-01-10) column 2, line 40 - line 55 column 4, line 59 -column 5, line 18 ---	1,3-6, 11,12
X	WO 95 09607 A (TONETTI MAURIZIO) 13 April 1995 (1995-04-13) page 4 -page 5; example 1 ---	1,3,4, 11,12
X,P	EP 0 865 787 A (DOW CORNING SA) 23 September 1998 (1998-09-23) claims 1,2 --- -/--	1,3-5, 11,12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

30 September 1999

Date of mailing of the international search report

13/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Boulois, D

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 40797 A (TRI POINT MEDICAL CORP) 19 December 1996 (1996-12-19) page 21, line 37 page 14, line 32 - line 38 page 19, line 19 - line 34 ---	1-9, 11-20
X	CHEMICAL ABSTRACTS, vol. 129, no. 17, 26 October 1998 (1998-10-26) Columbus, Ohio, US; abstract no. 211263, FAN MINGWEN ET AL: "Effect of Chlorhexidine varnish system on streptococcus mutant in fissure plaques" XP002117052 abstract	13-20
X	& FAN MINGWEN ET AL: "Effect of Chlorhexidine varnish system on streptococcus mutant in fissure plaques" ZHONGHUA KOUGIANG YIXUE ZAZHI, vol. 32, no. 5, 1997, pages 269-271, -----	13-20

Information on patent family members

International Application No.

PCT/US 99/09374

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5684042 A	04-11-1997	AU 4745497 A	03-08-1998
		AU 4911297 A	03-08-1998
		AU 5910698 A	03-08-1998
		EP 0856318 A	05-08-1998
		EP 0855191 A	29-07-1998
		JP 10192389 A	28-07-1998
		SG 66405 A	20-07-1999
		WO 9830090 A	16-07-1998
		WO 9830091 A	16-07-1998
		WO 9830092 A	16-07-1998
		US 5902594 A	-05-1999
		US 5762919 A	-06-1998
		US 5783177 A	-07-1998
			09-1998
			05-1998
US 4797282 A	10-01-1989		0-1986
			3-1991
			8-1989
			0-1986
			1-1991
			-1986
			-1992
			-1986
WO 9509607 A	13-04		3-04-1995
			23-10-1996
			24-07-1996
			22-07-1997
			18-08-1998
EP 0865787 A	23-		25-09-1998
			06-10-1998
WO 9640797 A	19-12-1996	US 5928611 A	27-07-1999
		AU 701219 B	21-01-1999
		AU 6262696 A	30-12-1996
		CA 2221260 A	19-12-1996
		CN 1186503 A	01-07-1998
		EP 0832137 A	01-04-1998